[go: up one dir, main page]

PL2167033T3 - Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus - Google Patents

Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus

Info

Publication number
PL2167033T3
PL2167033T3 PL08748829T PL08748829T PL2167033T3 PL 2167033 T3 PL2167033 T3 PL 2167033T3 PL 08748829 T PL08748829 T PL 08748829T PL 08748829 T PL08748829 T PL 08748829T PL 2167033 T3 PL2167033 T3 PL 2167033T3
Authority
PL
Poland
Prior art keywords
tacrolimus
dosage form
oral dosage
once daily
daily oral
Prior art date
Application number
PL08748829T
Other languages
English (en)
Other versions
PL2167033T4 (pl
Inventor
Per Holm
Tomas Norling
Anne-Marie Lademann
Original Assignee
Veloxis Pharmaceuticals A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2167033(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Veloxis Pharmaceuticals A/S filed Critical Veloxis Pharmaceuticals A/S
Publication of PL2167033T3 publication Critical patent/PL2167033T3/pl
Publication of PL2167033T4 publication Critical patent/PL2167033T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08748829T 2007-05-30 2008-05-30 Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus PL2167033T4 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700783 2007-05-30
DKPA200701573 2007-11-07
PCT/DK2008/050130 WO2008145143A1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus
EP08748829.2A EP2167033B1 (en) 2007-05-30 2008-05-30 Once daily oral dosage form comprising tacrolimus

Publications (2)

Publication Number Publication Date
PL2167033T3 true PL2167033T3 (pl) 2017-12-29
PL2167033T4 PL2167033T4 (pl) 2018-08-31

Family

ID=39766919

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08748829T PL2167033T4 (pl) 2007-05-30 2008-05-30 Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus

Country Status (10)

Country Link
US (7) US8685998B2 (pl)
EP (1) EP2167033B1 (pl)
CA (1) CA2688381C (pl)
DK (1) DK2167033T3 (pl)
ES (1) ES2634153T3 (pl)
HU (1) HUE033011T2 (pl)
LT (1) LT2167033T (pl)
PL (1) PL2167033T4 (pl)
SI (1) SI2167033T1 (pl)
WO (1) WO2008145143A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028023D1 (de) * 2003-08-29 2010-08-19 Lifecycle Pharma As Tacrolimus enthaltende feste dispersionen
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
WO2009080030A1 (en) * 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
TWI494108B (zh) * 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
EA027869B1 (ru) 2010-02-17 2017-09-29 Велоксис Фармасьютикалз А/С Стабилизированная композиция такролимуса
US20120203573A1 (en) 2010-09-22 2012-08-09 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
US20120072231A1 (en) * 2010-09-22 2012-03-22 I.D. Therapeutics Llc Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns
EP2589383A1 (en) * 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
FR2986532B1 (fr) * 2012-02-07 2015-03-13 Polymerexpert Sa Compositions polymeres metastables pour dispositifs d'injection d'implants ophtalmiques
WO2014179266A2 (en) 2013-04-29 2014-11-06 The Johns Hopkins University Wound healing via autologous stem cell mobilization
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
RU2018115334A (ru) 2015-10-09 2019-11-11 Ацея Терапьютикс, Инк. Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
GB201600376D0 (en) 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
CN114469847B (zh) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 他克莫司栓剂及其制备方法和用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (ko) 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5601844A (en) 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
TR200002771T2 (tr) 1998-03-26 2001-02-21 Fujisawa Pharmaceutical Co.,Ltd. Devamlı salımı olan preparatlar
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc DRUG DISPERSION SYSTEM FOR THE AVOIDANCE OF PHARMACOKINETIC INTERACTIONS BETWEEN ACTIVE SUBSTANCES AND METHODOLOGY THEREOF
WO2001095939A1 (en) 2000-06-12 2001-12-20 Smithkline Beecham Corporation Novel solid dispersion compositions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
ES2739852T3 (es) 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
CN1819817A (zh) 2003-07-09 2006-08-16 株式会社钟根堂 一种泰克利玛的固体分散体
SI1663217T1 (sl) 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
DE602004028023D1 (de) 2003-08-29 2010-08-19 Lifecycle Pharma As Tacrolimus enthaltende feste dispersionen
US20070122482A1 (en) 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
NO320286B1 (no) 2003-11-19 2005-11-21 Dag Herman Zeiner-Gundersen Turbin for kraftproduksjon
EP1729741A2 (en) 2004-03-03 2006-12-13 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AU2005221427B2 (en) 2004-03-18 2008-09-25 Panacea Biotec Ltd. Novel compositions for topical delivery
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1835889A1 (en) 2004-12-15 2007-09-26 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
KR100678824B1 (ko) 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
KR20070121758A (ko) 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
EP1896075A2 (en) 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
KR100693461B1 (ko) 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
JP2008037808A (ja) 2006-08-07 2008-02-21 Astellas Pharma Inc タクロリムスカプセル剤
JPWO2008041553A1 (ja) * 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
KR20100014629A (ko) * 2007-03-29 2010-02-10 파나세아 바이오테크 리미티드 타크로리무스의 변형제형
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus

Also Published As

Publication number Publication date
US20210046054A1 (en) 2021-02-18
US20160243091A1 (en) 2016-08-25
EP2167033A1 (en) 2010-03-31
US8664239B2 (en) 2014-03-04
EP2167033B1 (en) 2017-04-19
HUE033011T2 (hu) 2017-11-28
US20210046055A1 (en) 2021-02-18
US20110275659A1 (en) 2011-11-10
PL2167033T4 (pl) 2018-08-31
US11123331B2 (en) 2021-09-21
US10864199B2 (en) 2020-12-15
US11110081B2 (en) 2021-09-07
US20120029009A1 (en) 2012-02-02
US20140179731A1 (en) 2014-06-26
US20100105717A1 (en) 2010-04-29
LT2167033T (lt) 2017-08-10
SI2167033T1 (sl) 2017-08-31
DK2167033T3 (en) 2017-08-14
US8685998B2 (en) 2014-04-01
CA2688381C (en) 2016-10-11
WO2008145143A1 (en) 2008-12-04
CA2688381A1 (en) 2008-12-04
ES2634153T3 (es) 2017-09-26

Similar Documents

Publication Publication Date Title
LT2167033T (lt) Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą
IL206159A0 (en) Oral pharmaceutical dosage forms
PT2077729E (pt) Formas orais probióticas
PL2399580T3 (pl) Farmaceutyczne postacie dawkowania
IL205160A0 (en) Oral dosage forms comprising licarbazepine acetate
IL207128A0 (en) Pharmaceutical dosage form
EP2361081A4 (en) MULTI-PARALLEL INTRA-ORAL DOSAGE FORM AND USE THEREOF
GB0710439D0 (en) Oral dosage form
ZA200903858B (en) Pharmaceutical dosage form
IL200619A0 (en) Novel dosage form
GB0721332D0 (en) Medicaments
GB0616794D0 (en) Solid dosage form
EP2114418A4 (en) ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
GB0625783D0 (en) Medicament
GB0822124D0 (en) Oral dosage form
SI2008940T1 (sl) Dozirna steklenica
GB0615064D0 (en) Medicament
GB0717450D0 (en) Medicament
LT2174652T (lt) Peroralinės farmacinės desmopresino kompozicijos
GB0721333D0 (en) Medicaments
GB0615814D0 (en) Medicament
ZA200708369B (en) Medicament
GB0704123D0 (en) Dosage form
HK1133593A (en) Oral cephalotaxine dosage forms